WOW 1-3: Thinly traded Cel-Sci (CELI), BioTime (BTIM) and Biomerica (BMRA) generated some sudden excitement last week. CELI gained $3.937 to $12.937 on 1.6 million shares traded on Tuesday, when it announced Japanese patent approval for its Multikine cytokine cocktail. Volume again ballooned on Thursday, to 2.7 million shares, after CEO Geert Kersten "had about 10 minutes of glory on CNBC" just prior to the opening.

CELI, which finished the week up $2.375 to $11.625, has made sweeping moves in recent weeks. It gained $3.125 to $11.125 in the week ended May 31 after announcing the start of a Phase I study of Multikine in prostate cancer. The following week, it shed $1.875 despite encouraging mouse data for its HGP-30 vaccine in HIV. The company, which has 6.3 million shares outstanding, estimates that it has 15,000 shareholders, a legacy from darker days in 1995, when the stock traded at about $2.75 and fell off the institutional radar. News on the horizon includes expanded discussion of its HIV results at the International